NGM Biopharmaceuticals Get $51M
South San Francisco-based NGM Biopharmaceuticals said today that it has closed on the first tranche of a $51, Series B round of funding. The round came from The Column Group, Tichenor Ventures, LLC, Prospect Venture Partners, Rho Ventures, and others. According to NGM, it has named McHenry (Mac) T. Tichenor, Jr. to its board as part of the funding. Tichenor is a Managing Member of Tichenor Ventures. NGM is targeting biopharmaceuticals to help restore glucose balance in patients with type 2 diabetes.
posted on Monday, March 15, 2010 (Link to more information)
Related companies:
NGM Biopharmaceuticals
Related stories:
> Itero Biopharmaceuticals Raises $21M
> CiVi Biopharma Takes $40M
> NGM Biopharmaceuticals Gets $50M For Diabetes, Obesity Treatments
> Interwest Discloses First Investments Out Of Fund X
> FLX Bio Picks Up $60M
silicontap.com Home